Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

BA-BE Studies: SOP for Logging Receipt of Samples from Clinical Site – V 2.0

Posted on By

BA-BE Studies: SOP for Logging Receipt of Samples from Clinical Site – V 2.0

Standard Operating Procedure for Logging Receipt of Samples from Clinical Site in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/193/2025
Supersedes SOP/BA-BE/193/2022
Page No. Page 1 of 8
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To establish a standardized procedure for receiving, inspecting, and logging biological samples such as plasma or serum received from the clinical site to the bioanalytical laboratory in bioavailability/bioequivalence (BA/BE) studies.

2. Scope

This SOP applies to all biological sample shipments from the clinical unit to the bioanalytical facility for analysis during BA/BE studies conducted at [Organization Name].

3. Responsibilities

  • Sample Custodian: Receives, verifies, and logs samples upon arrival.
  • Courier Personnel: Delivers samples and provides signed transport documents.
  • Bioanalytical QA: Verifies chain-of-custody and compliance with transport conditions.
  • Bioanalytical Head: Ensures procedures are followed and discrepancies resolved.
See also  BA-BE Studies: SOP for Stability Testing of Analyte in Plasma - V 2.0

4. Accountability

The Bioanalytical Department Head is accountable for ensuring that the receipt and documentation of clinical samples meet GCP and GLP requirements, and that sample integrity is maintained.

5. Procedure

5.1 Pre-Arrival Notification

  1. Clinical site staff informs the receiving lab at least 2 hours before sample shipment.
  2. Details to be shared:
    • Study Code
    • No. of Samples
    • Shipment Date & Time
    • Courier Name & Tracking
  3. Receiving team ensures freezer space and staff readiness.

5.2 Receipt of Samples

  1. Upon arrival:
    • Check external condition of container (no leakage, breakage, tampering).
    • Record ambient temperature if temperature logger is provided.
  2. Accept the consignment only if:
    • Seal is intact
    • Temperature maintained as per requirement (e.g., ≤ −20°C)
  3. Sign off the Sample Transfer Form provided by courier (Annexure-1).

5.3 Verification of Sample Details

  1. Open container in designated receiving area using PPE.
  2. Cross-check sample labels with the Sample Inventory Sheet provided by the clinical site.
  3. Verify:
    • Subject ID
    • Time point
    • Number of vials
    • Sample condition (intact label, no leakage/frosting)
  4. Document discrepancies in Annexure-2: Sample Receipt and Verification Log.
See also  BA-BE Studies: SOP for Interim Clinical Monitoring Reports - V 2.0

5.4 Logging and Storage

  1. Assign a Sample Receipt Log ID to the consignment.
  2. Record all sample details in the Sample Receipt Log Book (Annexure-3).
  3. Transfer samples to appropriate freezer (−20°C or −70°C).
  4. Label storage rack with:
    • Study Code
    • Receipt Date
    • Freezer Number

5.5 Reporting and Resolution

  1. Notify clinical site and QA of:
    • Missing samples
    • Unlabeled/partially labeled vials
    • Improper temperature on arrival
  2. Complete a Sample Receipt Deviation Form if any issues are found (Annexure-4).
  3. All forms and logs must be signed and archived in the Study Master File (SMF).

6. Abbreviations

  • BA/BE: Bioavailability/Bioequivalence
  • SOP: Standard Operating Procedure
  • QA: Quality Assurance
  • SMF: Study Master File

7. Documents

  1. Sample Transfer Form – Annexure-1
  2. Sample Receipt and Verification Log – Annexure-2
  3. Sample Receipt Log Book – Annexure-3
  4. Sample Receipt Deviation Form – Annexure-4

8. References

  • ICH GCP E6(R2)
  • US FDA Bioanalytical Method Validation Guidance (2022)
  • GLP Guidelines – OECD 14
See also  BA-BE Studies: SOP for Informed Consent Process Execution - V 2.0

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Sample Transfer Form

Study Code BE/XYZ/2025/07
Date of Shipment 16/04/2025
No. of Samples 320
Courier SafeTemp Logistics
Shipped By Dr. Sunita Reddy

Annexure-2: Sample Receipt and Verification Log

Subject ID Time Point Vial Count Condition Remarks
SUB001 0 hr 2 Good —

Annexure-3: Sample Receipt Log Book

Log ID Date Study Code No. of Samples Freezer
LOG/193/25 17/04/2025 BE/XYZ/2025/07 320 FZ-04

Annexure-4: Sample Receipt Deviation Form

Date 17/04/2025
Deviation One sample missing (SUB015, 4hr point)
Investigated By QA Officer
Action Taken Clinical site informed, CAPA initiated

Revision History:

Revision Date Revision No. Details Reason Approved By
01/01/2022 1.0 Initial Issue New SOP QA Head
17/04/2025 2.0 Expanded logs and deviation documentation Audit Compliance QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: Analytical Method Development: Development of Sterility Test Protocol – V 2.0
Next Post: Elixir Department: SOP for Sampling for Stability from Manufacturing Tank – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2026 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version